[Determination and comparison of pulmonary function with anthropometric indexes in asthmatic and non-asthmatic obese teenagers].
BACKGROUND
Anomalies in pulmonary function tests in obese are oriented predominantly to restrictive pathology, not been demonstrated efficiently.


OBJECTIVE
To determine and compare pulmonary function tests (PFT) with anthropometric measurements by spirometry and plethysmograph in asthmatic obese (AO) and non-asthmatic obese (NAO) adolescents.


METHODS
Cross-sectional study, with 86 adolescents. Obesity was defined as body mass index (BMI) greater to 95% percentile according to CDC and asthma, on the basis of the definition and criteria of GINA guidelines. Clinical history was made, doing anthropometric measures and PFT with determination of: forced vital capacity with maximal expiratory effort, forced expiratory volume in the first second, specific resistance and conductance.


RESULTS
The average age was 12.68 years +/- 1.85, 39 were NAO and 47 AO, who had intermittent to persistent asthma, 14 patients received 200 mcg budesonide/day at least 4 weeks previous to the study. The average values in AO and their standard error for anthropometry were: weight: 68.5 +/- 13.6 kg, height: 154.58 +/- 9.1 cm, BMI: 28.27 +/- 3.24 kg/m2, abdominal circumference (AC): 98 +/- 8.85 cm and hip circumference (HC): 100 +/- 8.87 cm, in NAO: weight: 76.1 +/- 14.7 kg, height: 155.7 +/- 7.85 cm, BMI: 31.04 +/- 4.46 kg/m2, AC: 102 +/- 11.05 cm and HC: 103.28 +/- 10.6 cm.


CONCLUSIONS
In NAO post-beta2 Raw diminished whereas Sgaw increased. Greater BMI in AO displayed greater FEV1 with statistic significance. Obstructive ventilator pattern mechanics was observed in both groups.
Zepeda Ortega
Benjamín
B
Departamento de alergia e inmunología clínica pediátrica, Hospital Infantil de México Federico Gómez, México DF.
Ito Tsuchiya
Fernando M
FM
Espinola Reyna
Gerardo A
GA
Adell Gras
A
A
del Río Navarro
Blanca E
BE
D000293:Adolescent; D000318:Adrenergic beta-Agonists / Q000494:pharmacology / Q000627:therapeutic use; D000403:Airway Resistance; D000886:Anthropometry; D018927:Anti-Asthmatic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001249:Asthma / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology*; D001827:Body Height; D015992:Body Mass Index; D001835:Body Weight; D019819:Budesonide / Q000627:therapeutic use; D002648:Child; D003430:Cross-Sectional Studies; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D008800:Mexico / Q000453:epidemiology; D009765:Obesity / Q000150:complications / Q000453:epidemiology / Q000503:physiopathology*; D014505:Urban Population / Q000706:statistics & numerical data; D014797:Vital Capacity; D055105:Waist Circumference; D049629:Waist-Hip Ratio
D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents; D019819:Budesonide